Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2018 08:00 ET | Source: Relypsa, Inc.

Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 2018

REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the Academy of Managed Care Pharmacy’s AMCP...
October 09, 2018 16:00 ET | Source: Relypsa, Inc.

Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2018

REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the American Society of Nephrology (ASN) Kidney...
October 01, 2018 08:00 ET | Source: Relypsa, Inc.

Relypsa Announces Appointment of Patrick Treanor as President

REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced the appointment of Patrick Treanor as president on an interim basis, effective...
May 08, 2018 08:00 ET | Source: Relypsa, Inc.

Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food

REDWOOD CITY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the United States (U.S) Food and Drug Administration (FDA) approved a...
April 16, 2018 16:00 ET | Source: Relypsa, Inc.

Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders

REDWOOD CITY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that it has awarded three research grants to supplement institutional funding...
April 11, 2018 08:00 ET | Source: Relypsa, Inc.

Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings

REDWOOD CITY, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a pooled analysis of three clinical trials evaluating the effects...
November 03, 2017 17:30 ET | Source: Relypsa, Inc.

Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2017

REDWOOD CITY, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a prespecified analysis of data from the Phase 4 TOURMALINE study of...
July 21, 2017 08:00 ET | Source: Relypsa, Inc.

Relypsa Announces European Approval of Veltassa® to Treat Adult Patients with Hyperkalemia (Elevated Blood Potassium Levels)

Today’s European Commission approval is the second worldwide; in the U.S., more than 33,000 patients have been treated with Veltassa since it was approved by the FDA in 2015Patients with advanced...
April 19, 2017 18:00 ET | Source: Relypsa, Inc.

Relypsa Presents Veltassa® Phase 4 Data Showing Consistent Efficacy and Safety Whether Taken With or Without Food in Patients with Hyperkalemia

In the study, Veltassa, the first new medicine approved by the FDA for hyperkalemia in more than 50 years, showed a consistent potassium-lowering effect and safety profile whether taken with or...
February 13, 2017 16:30 ET | Source: Relypsa, Inc.

Relypsa Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics

Phase 1 studies with 12 oral medications commonly used in hyperkalemic patients with chronic kidney disease showed minimal risk for drug-drug interactions with Veltassa when other oral drugs are...

Next Page keyboard_arrow_right